



# **OncoBREAST Dx - Final Report**

### **Patient Information**

Identification Data		General Biochemistry		<b>Blood Drawn Realization</b>	
HRN:	BRE00000273	Creatinine (mg/dL):	1.00	Blood Drawn Date:	11-10-2017
ID Card:	Unknown	ASAT (U/L):	8.00		
		ALAT (U/L):	12.00	Urine Tumor Markers	
Personal Data		GGT (U/L):	7.00	8-OHdG (ng/mL):	11.10
Age (years):	47	Total Bilirubin (mg/dL):	1.00		
		Hemolized Sample:	No	<b>Urine Drawn Realization</b>	
Comorbidities				Urine Drawn Date:	11-10-2017
Atherosclerosis: No		Serum Tumor Markers			
Chronic Liver Disease: No		CA 15.3 (U/mL):	19.70	Lifestyle	
Diabetes Mellitus 1 or 2:		CEA (ng/mL):	1.60	Smoking:	Currently
Jaundice: No		EGFR (ng/mL):	5.00		
Renal Failure: No		NGAL (ng/mL):	4.60		
		NSE (ng/mL):	7.00		

#### Outcome

#### Results

Some Tumor Markers are outside the reference range and suggest malignancy.



# **Comments**

In absence of comorbidities that are well-known source of False Positive (FP) in healthy patients by increasing some Tumor Markers levels, whole Tumor Markers levels suggest malignancy.

## **Conclusions**

WE SUGGEST BREAST CANCER. THE 2016 ICD-10-CM DIAGNOSIS CODE IS C50 (MALIGNANT NEOPLASM OF BREAST).

This report has been generated from the data entered on 19-12-2017 10:55:02 UTC/GMT.

#### **Disclaimer**

This Multiple Biomarkers Disease Activity Algorithm (MBDAA) for Breast Cancer has been developed for the exclusive use by healthcare professionals, and solely as a Clinical Decision Support System (CDSS), not as an unique element for diagnosis. The algorithm bears a Sensitivity = 82.3%, Specificity = 85.7%. Please note, negativity of the Tumor Markers does not exclude at 100% the possibility of a malignant epithelial tumor.

**Bioprognos SL** 

Benet Mateu, 40 - 08034 Barcelona (Spain)

Email: info@bioprognos.com Website: www.bioprognos.com



Technical Responsible

Lorena Lendinez Chief Scientific Officer Bioprognos SL